6th December 2024
6th December 2024
The Company is pleased to announce progress on recent developments regarding the licence transaction and the DaaP sale.
We confirm that both transactions will occur independently and concurrently. In acknowledgement of the previous statement made on 31st July regarding notifications from the Paying Agent, due to successful negotiations, licence notifications are no longer required before the DaaP sale.
There are two Paying Agents, one for the licence and the other appointed by the DaaP buyer. The Paying Agent for the licence will issue notifications for the funds it holds. The buyer’s Agent, with a reconciled share register, will notify shareholders regarding the distribution of funds for the DaaP sale after the buyer’s announcement.
Licence notifications and the DaaP sale announcement will take place before Friday 10th January 2025.
The licensee is a North American communications company. Our technology will be deployed through their international arm which is one of the leading smart and safe cities technology providers.
The DaaP is a pre- and post-operative platform for patient care utilising various biomarkers, providing physicians with a 360 degree view of the patient’s clinical status, in preparation for procedures and to determine improvements post-procedure.
The Company is confident in its ongoing operations and looks forward to the fulfilment of both distribution processes. We apologise for the previous and unforeseen delays.
The Company remains under strict non-disclosure agreements. All further updates will be published on www.cloudtag.com.